Insurance by BogdanovaThe Encyclopedia of Insurance and Risk Science

RESEARCH DOSSIER

Health Insurance Exchange Competition and Plan Pricing

Abstract. Health insurance exchanges organize competition through eligibility, plan certification, risk pooling, the presentation of alternatives, premium assistance, and the allocation of expected medical costs. Their pricing outcomes therefore arise from several linked markets: insurers compete for enrollment, providers bargain over payment, households choose contracts with different financial and clinical attributes, and public authorities regulate transfers and subsidies. This monograph examines the relationship between plan differentiation, risk-adjusted premiums and bids, consumer search, and equilibrium outcomes, with primary emphasis on the United States Affordable Care Act (ACA) individual marketplaces and disciplined comparison with the Netherlands and Switzerland. It distinguishes the price paid by the enrollee from the issuer's gross premium, the benchmark used to calculate assistance, the risk-adjustment transfer, and the net resource cost of care. Original peer-reviewed studies, federal legal instruments, regulatory publications, administrative data descriptions, official foreign-system documents, and recent concentration evidence provide the evidentiary base. A formal accounting decomposition and explicitly hypothetical premium examples demonstrate how a fall in a benchmark premium can increase a subsidized buyer's net payment for a different plan, how plan choice can alter risk composition without altering lawful individual rating factors, and why more listed contracts need not mean greater independent insurer competition. The analysis identifies conditions under which entry lowers gross premiums, differentiation protects access, choice architecture affects demand, and benchmark-linked subsidies reshape pricing incentives. Evidence from particular populations and regulatory years is interpreted within its identification limits. This is an original comparative analytical synthesis; it does not claim a newly invented theoretical system, new administrative microdata, or original causal effect estimates.

Keywords: Health insurance exchanges; managed competition; qualified health plans; benchmark premiums; premium tax credits; risk adjustment; adverse selection; insurer entry; market concentration; consumer search; plan standardization; choice architecture; provider networks; health financing; comparative insurance markets.

Introduction

An exchange is an institution that makes a defined set of insurance contracts accessible to eligible buyers under specified enrollment and product rules. It can reduce the cost of discovering offers, coordinate eligibility and financial assistance, enforce minimum contract requirements, and publish comparable information. Its competitive significance depends on what contracts are actually available to a particular household, how many independent organizations can supply them, and how the household's price responds to the prices of competing plans.

The U.S. ACA exchanges illustrate the interaction of private bids and public rules. The Internal Revenue Code ties the premium tax credit to an applicable second-lowest-cost silver benchmark subject to eligibility and statutory limits (United States, 2026). Federal risk-adjustment methodology requirements independently govern transfers among issuers. These are different operations: a consumer-facing tax credit, a gross insurance rate, and a risk-adjustment transfer cannot be treated as one number. Moreover, the exchanges include plans varying in metal category, provider network, formulary, cost sharing, service geography, and issuer identity, while the legally admissible individual rating factors are limited.

The historical literature supplies a clear starting result. Dafny, Gruber, and Ody (2015) estimate that additional first-year marketplace competition would have lowered the second-lowest-cost silver premium, but their initial-marketplace pricing study concerns the 2014 environment and specific identification assumptions. The newer competition review by Gaynor and Starc (2026) integrates market power, adverse selection, consolidation, and regulation. The October 2026 GAO concentration report documents more recent structural patterns without furnishing a randomized causal estimate of each local premium difference. These sources establish complementary, distinct forms of evidence.

This dossier addresses three research questions. First, which forms of plan differentiation improve effective choice and which fragment comparable price competition? Second, how do actuarial costs, risk equalization, benchmark subsidies, and pricing rules combine in a feasible premium? Third, how do search frictions and institutional design alter the observed equilibrium, and which conclusions can be transported between countries or years? The analysis is based on a structured documentary and literature synthesis. All numerical demonstrations marked hypothetical are analytical illustrations, not estimates of actual marketplace behavior.

Conceptual, Historical, and Documentary Foundations

Exchange competition as an institutional arrangement

Competition may take place at the insurer-parent level, legal-issuer level, product level, provider-network level, or individual-policy level. An issuer can list dozens of plans while representing only one parent organization; several issuers can rely on the same hospital network; several superficially similar plans can differ in their access to a particular physician or medicine. Measuring competition by a count of plan identifiers consequently answers a different question from measuring concentration of independent insurers or the substitutability of medical care. The 2026 KFF participation analysis explicitly groups issuers by parent company and notes geographic and product-level availability limitations (Ortaliza et al., 2026).

A plan's price has several layers. Gross premium is the contractual amount charged before applicable financial assistance; net premium is the amount a particular enrollee pays after an allowable subsidy; actuarial value is a population-average share of covered medical spending, not an individual's guarantee of reimbursement; out-of-pocket cost depends on actual utilization, networks, exclusions, and specific plan design. The federal plan-category explanation defines metal levels principally by how covered costs are shared (HealthCare.gov, 2026). Premiums and expected out-of-pocket payments therefore belong in separate columns in both consumer comparison and scientific estimation.

The exchange itself also has a time dimension. Plans enter before a coverage year; regulators certify them; consumers select or renew during designated windows; enrollment is effectuated through premium payment as applicable; claims and risk-adjustment transfers are observed later. Entry expectations may reflect a previous year, whereas an ex post concentration measure describes realized enrollment after consumers choose. A model that uses post-enrollment concentration as if it were an externally predetermined cause of the same year's premium risks simultaneity.

The United States sequence and the changing rulebook

ACA marketplaces began offering individual coverage for 2014. Their early period had limited insurer participation in a number of rating areas; subsequent periods included entry, exit, consolidation, changes in subsidies, and revisions to qualified-health-plan requirements. Dafny, Gruber, and Ody's first-year counterfactual estimates are 5.4% lower for the second-lowest silver premium if a specified nonparticipant had entered and 11.1% lower under their broader hypothetical full-entry scenario; neither is a universal elasticity applicable to 2026 or 2027. Their identifying comparison and extrapolation assumptions are part of the result.

Recent administrative summaries confirm that the scale of marketplace participation has changed. CMS's 2026 open-enrollment report reports approximately 23.1 million plan selections or automatic reenrollments during the 2026 open-enrollment period, a selection measure that must be distinguished from continuously effectuated coverage (CMS, 2026a). The 2026 enrollment public-use documentation describes the geographic and demographic reach of different released tabulations and their platform-specific limitations (CMS, 2026b).

Competition rules are not static. The final 2027 payment notice, issued May 15, 2026, and effective July 20, 2026, removes federal-platform standardized-plan offering requirements and limits on nonstandardized options for the relevant 2027 rules, while revising other exchange, market integrity, and risk-adjustment provisions (CMS, 2026c). The authoritative Federal Register text is the controlling regulatory version for statements about that rule (HHS, 2026). The important analytical distinction is between removal of a specific federal offering mandate and the continuing ability of states or insurers to shape plan design under applicable law. A study based on standardized menus in an earlier year cannot be assumed to observe the same institutional treatment in 2027.

Document hierarchy and analytical scope

The evidence is organized by its function. Statutes and effective regulations define legal admissibility; CMS data documentation defines what a released administrative field measures; primary peer-reviewed studies estimate behavioral or market mechanisms for specific samples; official foreign-government descriptions define other systems; policy research provides descriptive context and transparent secondary aggregation. None of these categories can substitute for another. A statistically significant price association cannot amend a statute, and a statutory premium formula cannot establish a behavioral elasticity.

The population scope likewise matters. An ACA individual exchange is distinct from employer-sponsored insurance, Medicare Advantage, Medicare Part D, and Medicaid managed care. The Gaynor–Starc competition synthesis covers several U.S. insurance segments, but estimates from one segment are transported to the individual exchanges only after showing the relevant similarity of choice sets, risk pooling, purchasing rules, and contracts. This study uses cross-market evidence to understand mechanisms and keeps ACA-specific empirical claims attached to ACA-specific sources.

Plan Differentiation and Choice Sets

Products, access, and horizontal differentiation

Insurers may differentiate by price, actuarial value, deductible, coinsurance, copayments, networks, referral arrangements, medication coverage, customer support, service areas, and convenience. A broader menu increases the possible match between a consumer's needs and an available contract when those differences are real and intelligible. It may also impose additional search costs and permit products with similar labels but materially different provider access to be presented as substitutes.

Differentiation has a vertical component, in which buyers may generally rank greater financial generosity more highly at a fixed price, and a horizontal component, in which two people prefer different networks or service arrangements. A plan with a narrow network can carry a lower premium while imposing substantial access costs on a patient whose specialist is out of network. Evaluating this plan as a pure price improvement would omit the welfare value of continuity and treatment accessibility. Conversely, preserving an extensive network can have real costs and must not be assumed desirable for every enrollee.

U.S. official premium-setting guidance states that location, age, tobacco use, plan category, and family coverage can influence premiums, subject to legal and state limits, while health history and sex do not directly determine an individual's lawful Marketplace premium (HealthCare.gov, 2026a). This should be read together with the distinction between allowable rating factors and issuer calculations of portfolio costs: insurers can forecast expected morbidity for solvency and risk adjustment without charging a specific person a diagnosis-based rate.

Choice sets are household-specific

Let J(h,t) denote the set of plans legally offered and accessible to household h at time t. This set depends on residence and service area, eligibility, household composition, plan-year enrollment windows, the availability of particular metal categories, and whether a usable provider network is offered. The observed number of contracts listed statewide can substantially exceed the number available at a particular address. A county-level summary may also overstate the precise available menu when plan availability varies by ZIP code.

The KFF 2026 insurer census reports an average of 9.0 participating insurers per state, down from 9.6 in 2025, and 165 counties with only one offering insurer under its parent-company counting methodology (Ortaliza et al., 2026). These are descriptive geographic statistics, not the number of distinct substitutes accessible to any given individual. The study itself notes limitations from combining rating-area and county representations, which matter especially for metal-level-specific counts.

One practical requirement follows: comparative claims should separately report at least (a) independent parents, (b) qualified legal issuers, (c) plans and variants, (d) qualifying local offers for a defined household, and (e) network overlap. Counts should be weighted by relevant population or enrollment when the question concerns the experience of a typical consumer. Rural access and urban concentration can differ strongly even when a state's average issuer count is unchanged.

Standardization as a choice intervention

Standardization usually reduces variation in specified cost-sharing attributes across products while leaving price, brand, and other attributes differentiated. It can make price comparisons easier, though it may remove valuable designs and alter which attributes consumers attend to. In their Massachusetts exchange natural-experiment study, Ericson and Starc (2016) report that consumers selected more generous plans and different brands following a policy that standardized financial plan features and simplified presentation. Their published analysis of plan standardization finds no corresponding increase in price sensitivity and separates effects of changed availability from changed valuation. Standardization therefore has an empirically demonstrated composition effect but is not a mechanically guaranteed competition-enhancing treatment.

The policy history creates a useful institutional contrast with the federal 2027 reversal. In earlier federal-platform policy years, standard-plan display and limits on nonstandard offerings were designed to constrain menu complexity. The 2027 final regulatory notice discontinues those specific requirements. This transition creates research opportunities but also complicates before-after comparisons: issuer composition, subsidies, risk, medical trend, and regulatory requirements may change simultaneously. A difference between 2026 and 2027 plan choice cannot automatically be attributed to menu liberalization.

Networks as an endogenous product dimension

Insurers negotiate provider payment rates and organize networks partly to create a viable price-quality combination. Providers in concentrated local hospital markets may have bargaining leverage, and network exclusion can reduce an insurer's contracting cost while changing access. Price comparisons across issuers therefore cannot isolate insurance-sector competitiveness from upstream medical-provider market power. The 2026 competition review places insurance concentration and provider bargaining within a broader market-power discussion (Gaynor and Starc, 2026).

An adequate evaluation of a differentiated plan should record geographic reach, network breadth and overlap, formulary features, essential covered services, and complaint or access measures where reproducible data exist. Listing a provider in a directory is not equivalent to demonstrating timely appointment access; contract network data and verified realized access are different evidence types. Network issues affect both demand elasticity and insurer bargaining, making them essential state variables rather than merely qualitative consumer amenities.

Risk-Adjusted Premiums, Bids, and Subsidy Incidence

Four monetary objects

For issuer i, region r, and year t, let P denote the gross premium, A the premium assistance available to an eligible household, N the net household premium, and T the risk-adjustment transfer received by an issuer, with a positive T representing net receipt. The elementary accounting relation for a fully usable credit is N = max(0, P − A), while the general legal calculation requires household-specific eligibility, applicable credit caps, and reconciliation provisions. At the issuer level, a deliberately simplified expected underwriting margin per member is M = P + T − C − E, where C is expected covered claims at negotiated prices and E includes administration, exchange assessments, and other relevant expenses. Taxes, reserves, capital cost, and program-specific settlement amounts may require additional terms. These are accounting decompositions, not estimated behavioral equations.

The premium tax-credit statute and benchmark calculation regulation connect an eligible household's credit to the second-lowest-cost silver premium applicable to its circumstances, subject to applicable law (United States, 2026; Treasury, 2026). The federal risk-adjustment regulation instead specifies publication of risk-model factors and transfers, including plan-average actuarial risk (HHS, 2026a). Conflating A with T would falsely treat a consumer subsidy as a payment based on an individual diagnosis.

A bid may mean an insurer's proposed gross rate in everyday marketplace language, but this is not the same institutional object as a Medicare Advantage or a government procurement bid. ACA qualified health-plan rates are subject to statutory rating and review rules. A technical paper should state exactly what is being bid: premium per age cell, a plan's approved rate schedule, a network contract, or the forecast used to submit a rate filing.

Benchmark-linked pricing and a reproducible example

For an eligible consumer whose calculated premium tax credit is positive and below the chosen plan's gross premium, a local simplified relation is A = B − H, where B is the household-applicable second-lowest silver benchmark and H is its required contribution under the applicable tax schedule. Consequently N(j) = P(j) − B + H for a chosen plan j, as long as the boundaries do not bind. The derivative of that net premium with respect to a competing benchmark B is minus one when P(j) and H remain fixed. This derivative is an arithmetic partial effect, not a prediction that an insurer can reduce B without changing the rest of the market.

Consider an explicitly hypothetical market with an eligible person's monthly required contribution H = $150, a benchmark B = $600, and another eligible plan's gross premium P(j) = $580. The simplified credit is $450 and that plan's net premium is $130. Suppose competitive repricing lowers the benchmark to $550 while the chosen plan stays at $580. The credit falls to $400, so the net premium for the unchanged plan increases to $180. If the chosen plan also cuts its own gross premium to $530, its net premium becomes $130 again. Thus a falling benchmark can reduce public premium assistance while redistributing the benefit among plans, households, and the public budget. All numbers are invented for transparent demonstration, with no policy-year eligibility claim or causal estimate.

The individual marketplace's subsidy design produces unusual pricing incentives because the relative position of a silver plan in the local premium ranking matters. A small premium change can alter which plan becomes the second-lowest silver benchmark. Where this occurs, the change in subsidy is discontinuous in the identity of the benchmark even when the prices themselves vary continuously. An empirical model should recalculate the benchmark for each hypothetical price vector rather than simply subtracting an unchanged national subsidy average. It should also distinguish households whose credits are capped, who receive no credit, or who qualify for a different amount.

Expected costs, rating constraints, and risk adjustment

The insurer's expected gross premium must finance covered claim cost, administration, financial resilience, and the net effect of transfers and other program requirements. Predictions of morbidity, provider use, specialty medicine exposure, medical inflation, enrollment composition, and network price are part of prudent pricing. Yet lawful individual rating can be restricted even when actuarial expected claims vary across members. The Marketplace rating rules enumerate factors allowed in the federal consumer explanation, while the risk-adjustment statute and methodology operate across issuers.

The central selection mechanism is straightforward. If an insurer attracts members with expected claims above the market average while collecting standardized or constrained premiums, its margin worsens unless compensated by transfers, care management, or other legitimate efficiencies. Conversely, attracting predictably low-risk members can be profitable in an imperfectly adjusted system. Risk equalization reduces the incentive to select favorable risks by partially realigning expected revenue with expected covered cost. It can leave residual selection incentives because prognostic models are imperfect, incentives to code diagnoses exist, and realized costs contain stochastic and provider-price variation.

CMS's 2027 final rule text specifies a blend of 2021–2023 enrollee-level EDGE data for the 2027 HHS risk-adjustment model coefficients and continues the state transfer formula subject to the rule's other provisions (HHS, 2026b). These details should be stated for the 2027 benefit year rather than generalized to all years. Rulemaking establishes the method; it does not by itself show the empirical accuracy of risk adjustment for every small plan.

Concentration and gross premium determination

Insurer entry can change both price and costs. New competitors may compress margins, produce new network offerings, and change incumbent strategies. Entrants may also have less favorable provider bargaining terms, thinner enrollment, or higher fixed expenses. Causal assessment requires separating the pricing effect of competitor pressure from cost differences and market selection.

Dafny, Gruber, and Ody's counterfactual exchange-competition evidence suggests lower second-lowest silver premiums in their modeled early ACA settings (2015). The October 2026 GAO report documents the concentration of private health insurance enrollment using data through 2024, including a predominance of a small number of insurers in many state markets. Because concentration may itself reflect local costs, demand, regulation, and past merger decisions, its correlation with premiums is informative but is not automatically a structural causal response to an exogenous entrant.

Regulated competition produces a trade-off in rate regulation. A ceiling that is too restrictive relative to expected costs may discourage offers or produce narrower networks; permissive pricing in a concentrated area may allow markups. The welfare comparison therefore requires both coverage availability and the gross-to-net transfer structure. It cannot stop at the observed lowest premium.

Consumer Search and Equilibrium Outcomes

Information friction, inertia, and revealed choice

An exchange lowers some information costs by gathering offers and processing applications. The contract remains multidimensional, and medical use is uncertain. Consumers face difficulty converting a deductible, coinsurance schedule, formulary, and network into a meaningful expected annual financial and clinical outcome. Handel and Kolstad's administrative-and-survey analysis of insurance choice (2015) shows that information frictions and hassle costs have important consequences for estimated risk preferences and welfare. The studied setting is employer coverage; the evidence supports a mechanism rather than a direct exchange-specific effect-size transfer.

Let U(h,j) be household h's expected utility from plan j after accounting for net premium, uncertain out-of-pocket spending, risk protection, network accessibility, quality, and taste. The observed choice may reflect U together with a switching cost or imperfect information. A high observed market share can therefore be consistent with high consumer valuation, strong inertia, an artificially favorable default, or absence of local alternatives. Inference from a static market share alone cannot identify which mechanism dominates.

Default renewal is particularly important. An enrollee who remains with a plan when the benchmark or network changes may face a higher net premium without actively comparing all options. The CMS enrollment file definitions separate new, returning, and switching activity in the data available for 2026. Renewal observations should be interpreted with the applicable automatic-enrollment rules and the distinction between plan selection and final effectuation.

Price elasticity under a benchmark subsidy

Subsidized demand need not respond to the same prices as unsubsidized demand. An eligible household buying a plan whose premium changes while the benchmark remains fixed usually sees a corresponding change in its own net premium until relevant caps bind. But a price change by a benchmark-setting competitor can alter the credit on all eligible plans. The gross price elasticity of an issuer's enrollment and its net-price elasticity therefore refer to different variation.

A proper econometric specification must distinguish (1) own-plan gross price; (2) benchmark price and subsidy; (3) required household contribution; (4) nonprice plan attributes; and (5) the local choice set. Ignoring benchmark endogeneity can create a misleading estimate of competitive discipline, particularly in thin markets where one issuer can occupy several rank positions. Models should allow consumers to perceive price differences imperfectly and to value insurer brand or network continuity.

There is a subtle welfare issue: when the benchmark falls, a government budget can save money on assistance for a fixed eligible population, while some households in unchanged plans can face higher net payments. This is a transfer incidence statement, and any conclusion about total social welfare also requires demand, utilization, care quality, and tax-financing consequences. A lower benchmark is valuable information but not a sufficient welfare statistic.

Observed enrollment and the scale of choice

The 2026 CMS marketplace report records about 23.1 million selections, including automatic reenrollments (CMS, 2026a). The corresponding 2026 KFF participation assessment finds a decline in the average number of participating insurers from 2025 to 2026 (Ortaliza et al., 2026). These are jointly informative observations: substantial enrollment can coexist with fewer participating organizations. Their movements should not be read as proof that entry alone caused changes in take-up or that every selection produced an active policy throughout the year.

Price-level comparisons also demand care. KFF's benchmark-premium geographic series reports national and state benchmarks for 2026, including substantial geographic variation (KFF, 2026). The series combines and weights plan data under stated methods. State averages do not permit recovery of the exact benchmark applicable to a particular household, which depends on location and applicable demographic composition.

Choice overload, menus, and supplier strategy

The marginal benefit of one additional plan falls when it replicates existing contracts, especially if consumers cannot discern the difference. Conversely, an additional specialized network can be highly valuable to a group with previously unmet care needs. The market's relevant diversification is therefore the distribution of meaningful attributes, not the raw size of its catalog.

Ericson and Starc's Massachusetts plan-choice experiment demonstrates that changing standardization and presentation can shift demand toward greater generosity and different brands without a measured rise in price sensitivity. A dynamic pricing model that treats a menu change exclusively as an increase in the number of price competitors will miss the valuation and availability channels identified by the study. Insurers can respond by changing networks or cost-sharing terms instead of merely adjusting premiums.

Equilibrium and market exit

A useful dynamic sequence is: issuers forecast cost and enrollment; submit proposed rates and products; regulators apply certification and financial rules; households select or renew; risk composition and provider use emerge; transfers and claims are realized; issuers update expectations and entry decisions. Each stage affects later stages. A firm may lose money despite offering a high gross premium because of unfavorable claims or fixed costs; another may earn a margin through favorable provider contracts or a differentiated network while posting a lower premium.

Entry barriers include capital, statutory compliance, licensed network coverage, payment systems, actuarial forecasting, distribution access, and the need to survive enrollment volatility. Exit decisions can occur even when local premium growth is high. A dynamic study should model entry as a response to expected profit and policy uncertainty; a simple regression of premium on concurrent issuer count is insufficient.

Data, Model Validation, and Research Identification

Units of observation and source compatibility

Potential observational units include issuer-parent × rating area × plan year, qualified plan × ZIP code × coverage year, and household × local eligible plan × enrollment occasion. These must be linked with stable identifiers and dated crosswalks. The CMS Exchange public-use file catalog describes data from plan years 2014 through 2027, with 2027 files updated as the displayed offers change. Rate and plan-attribute files are useful for posted prices and characteristics; they are not a complete claims or consumer utility dataset (CMS, 2026d).

The 2026 CMS selection public-use documentation includes state-level and, for HealthCare.gov states, county and ZIP-level releases with specific eligibility and disclosure limitations (CMS, 2026b). Administrative selections should not be treated as distinct continuously insured persons without appropriate cleaning and effectuation information. PUF averages are often aggregated and may not identify within-cell covariance between prices, risk, and networks.

A research file should record the time stamp of every download, the applicable coverage year, rating-area boundaries, parent ownership, issuer and plan identifiers, displayed premiums, benchmark assignments, tax-credit rules, and network coverage. Changes in sample geography or source crosswalks must be reported rather than hidden in a time-series chart.

Measuring concentration

A parent-level Herfindahl–Hirschman Index is the sum of squared parent market shares in a defined market, with shares in fractions giving an index between zero and one. It increases when enrollment is concentrated among fewer parents. But a rating-area market is only a candidate definition: providers, policyholder mobility, and product differentiation may imply different substitution boundaries.

The 2026 GAO concentration study measures enrollment concentration in several insurance markets through 2024. It is valuable for structural description, yet the direction of influence can run from price to market share, from market share to bargaining power, and from past mergers or regulatory conditions to both. Researchers should test parent aggregation, county versus rating-area boundaries, enrollment versus offered-price weights, and measures of network overlap.

As a toy example, four parents each with 25% share produce HHI = 0.25. Two parents with 50% each produce HHI = 0.50. This arithmetic does not claim actual market estimates; it clarifies why a proliferation of plan variants from the same parents can increase the number of offers without changing concentration among independent competitors.

Identification designs

The ideal competitive-pricing analysis exploits exogenous changes in competitor presence or regulatory conditions, validates the exclusion restrictions, and observes prices and product characteristics before and after. Dafny, Gruber, and Ody's historical first-year comparison exploits variation connected to a national insurer's nonparticipation in federally facilitated marketplaces. Its assumptions about predicted shares and counterfactual entry constrain generalization.

Difference-in-differences designs can compare markets affected and unaffected by an exit or rule change, provided parallel-trend or suitable alternative identifying assumptions hold, treatment timing is defined, and spillovers are addressed. Network spillovers, pooled state finances, insurer multi-market pricing, and national subsidy shocks may violate a simple no-interference assumption. Instrumental variables require a defensible source of participation variation that affects premiums through competition rather than local cost or demand. Structural models require identification of utility parameters and cost functions, and should be compared against credible reduced-form moments.

Regression controls alone cannot cure mismeasurement of choice sets or reverse causation from anticipated claims to market entry. When data are limited to public aggregate files, descriptive analysis and transparently bounded simulations may be the appropriate scientific output. Labeling them as causal studies would overstate what the evidence can identify.

Robustness and sensitivity

At least six dimensions deserve sensitivity checks: parent versus issuer counts; county versus rating area; gross versus net premiums; fixed versus recomputed benchmark; observed plan selection versus effectuated enrollment; and pre- versus post-rule-change product definitions. For costs, further checks should distinguish allowed medical spending from paid insurance claims, insurer transfers from government assistance, and paid premiums from premium rates listed at enrollment.

A sensitivity table should show outcomes under alternative assumptions and reveal where qualitative conclusions change. For example, a finding that an extra plan lowers average gross premiums may disappear once plans are regrouped into parents or when an entrant offers only narrow-network products. This is not necessarily an error: the estimated object has changed. The analyst should then state which object is relevant to the institutional question.

The source audit for this monograph differentiates direct original research from data catalogs and policy summaries. It verifies source identity and the precise qualitative or numerical claim used. Full replication of raw CMS data, extraction of confidential claims files, and independent reestimation of published regression coefficients are outside the present documentary study. The arithmetic examples above are independently checkable from the stated invented numbers and identities.

Integrated International Synthesis and Research Conclusions

Netherlands: common benefits and regulated competition

The Netherlands provides a different institutional arrangement. The Dutch government's standard-insurance explanation describes compulsory basic insurance, a government-defined standard package, acceptance duties, and equal premiums across policyholders for the same basic contract irrespective of health or age (Government of the Netherlands, 2026). Insurers compete through premiums and arrangements for delivering the standard benefits within a regulated framework.

The Dutch risk-equalization administration explains transfers linked to the risk profiles of insurers' enrolled populations (Zorginstituut Nederland, 2026). This financing architecture aims to reduce rewards from selecting low-risk applicants. Because the Dutch basic contract and premium rules differ from ACA market rating and tax credits, a Dutch premium difference is not directly comparable to the net premium of a subsidized U.S. household.

The Dutch comparison isolates the governance role of benefit standardization and equalization. Defined core entitlements can concentrate competition on purchasing and service organization, yet insured persons may still face variation in contracted networks and practical access. The conclusion is institutional, not a quantified assertion that one country's competition regime has higher welfare than another's.

Switzerland: price transparency and premium approval

Swiss compulsory health insurance features an approved-premium system, standard premiums within legally defined groupings, and choices involving insurers, deductibles, and coverage models. The federal premium and cost-sharing explanation records the relevant resident pricing and contribution rules (Federal Office of Public Health, 2026a). The official premium comparison procedure explains the authority's approval and publication of insurer premiums and the government premium calculator, Priminfo (Federal Office of Public Health, 2026b).

The Swiss risk-compensation explanation identifies age, sex, prior hospital or nursing-home use, and pharmaceutical cost groups in the risk-equalization system, with levies balancing contributions (Federal Office of Public Health, 2026c). These variables belong to the equalization calculation, not a license to charge higher individual compulsory standard premiums for a given insurance model. This separation parallels the U.S. distinction between allowed individual premium factors and morbidity-dependent risk transfers, although the rules and precise models differ.

Swiss competition is also filtered through supervisory premium approval. A lower advertised premium may represent efficiencies, the insurer's mix of models and regional expenses, or other effects admissible under the regulatory system. Comparison requires holding the premium region, deductible, contract model, and eligibility constant. Applying the U.S. second-lowest silver benchmark formula to Swiss compulsory insurance would be a category error.

Cross-national comparison matrix

Dimension U.S. ACA individual exchanges Netherlands basic insurance Switzerland compulsory insurance
Core choice interface Exchange-certified locally available plans and subsidies Regulated selection of compulsory basic contracts Approved premiums and official comparison across insurers/models
Benefit comparability Essential-benefit requirements; differentiated metal levels and networks Government-defined standard package Statutory compulsory coverage with insurer/model and deductible distinctions
Individual rating Restricted factors including age/location under applicable law Equal premium for the same basic product irrespective of age or health Standard premium in legal geographic/model groupings, with specified exceptions
Risk compensation Federal or certified state issuer transfer methodology Risk-profile-based equalization through health insurance fund Risk compensation between insurers
Price paid by consumer Gross premium less applicable household tax credit Nominal premium and applicable assistance/contributions Approved premium, potentially with premium reductions subject to eligibility
Principal causal caution Benchmark-price endogeneity and changing rules Contract and purchasing differences despite common basic package Region, deductible, model, and supervisory approval

The matrix provides a controlled conceptual comparison; it does not identify a common causal estimator. Data definitions and financial flows must first be standardized before any cross-country numeric result could be defended. The underlying country rules are documented in the Dutch standard insurance requirements, Dutch equalization administration, Swiss premium approval explanation, and Swiss risk-compensation description.

Original analytical synthesis

Five conclusions follow when the documentary and econometric distinctions are maintained. First, a viable exchange needs meaningful substitutability among offers, not merely a large catalog. Plan identifiers are a weak proxy for independent competitive pressure where parents, networks, and geography overlap. Second, subsidy formulas can redistribute the consequences of price competition: reductions in the benchmark may lower public credits while increasing net premiums on an unchanged nonbenchmark plan. Third, risk adjustment and premium rating operate at different levels; efficient equalization can support competition for high-risk enrollees while imperfect equalization leaves selection incentives. Fourth, consumer search and renewal mechanisms can weaken price competition even with several technically available insurers. Fifth, policy and market histories are inseparable: the 2027 change in federal standardized-plan requirements must be specified before estimating a plan-menu effect.

These are analytical inferences derived from existing institutions, formal identities, and the cited evidence, not claims to a new authorial doctrine. They also carry practical research consequences. An exchange quality dashboard should report parent-level concentration, locally eligible plan options, normalized network accessibility, gross and net premiums, benchmark movements, effectuation and switching, and transfer-adjusted insurer margins where lawfully observable. Each variable answers a different part of the competition question. A single composite score would obscure mechanisms unless its weights and validation were independently justified.

The strongest unanswered questions are empirical: how does parent-level market entry affect both gross premiums and accessible care after accounting for provider contracts? Under what conditions does a benchmark-setting price reduction improve total welfare once tax expenditures and switching costs are included? How do the 2027 changes to standardized offerings affect menu complexity, actual plan choice, and risk sorting after controlling for simultaneous subsidy and insurer exits? Answering these requires appropriately timed administrative data, careful geographic linkage, and designs that address endogenous entry and demand.

Conclusion

Health insurance exchange competition is determined jointly by offered prices, the effective choice set, provider networks, consumer information, risk adjustment, and public payment rules. The gross premium, benchmark premium, household contribution, premium tax credit, and insurer risk transfer are separate variables with separate legal and economic effects. The framework for understanding these effects is supplied by statutory price formulas, contemporary federal rules, international insurance institutions, and empirical studies of market entry and choice behavior.

Historical U.S. evidence indicates that stronger insurer participation can reduce benchmark premiums in specified early ACA counterfactuals; recent concentration and participation reports demonstrate why competition remains a live issue while leaving contemporary causal effects to be estimated. Experimental and structural research shows that standardization and information architecture change how consumers evaluate plans, with consequences for brand selection and generosity. The 2027 federal changes make regulatory-period precision essential. The Netherlands and Switzerland show how competition can operate within alternative systems of mandatory coverage, administered risk equalization, and regulated premiums.

The resulting conclusion is a methodological and substantive one: price competition can be evaluated accurately only when the economist observes which entities genuinely compete, which plans a household can actually use, which price the household faces, and which public and private payments support the contract. This analysis completes an internally coherent documentary synthesis and establishes a replicable agenda for future empirical work without asserting unmeasured effects, creating a new theoretical doctrine, or assigning a publication date before an authorized release.

References

  • Centers for Medicare & Medicaid Services (CMS). 2026a. "Exchange Coverage Remains Near Record High as 23.1 Million Enroll in 2026." March 27, 2026. CMS original announcement.

  • Centers for Medicare & Medicaid Services (CMS). 2026b. "2026 Marketplace Open Enrollment Period Public Use Files." Data and definitions.

  • Centers for Medicare & Medicaid Services (CMS). 2026c. "HHS Notice of Benefit and Payment Parameters for 2027 Final Rule." May 15, 2026. Rule summary.

  • Centers for Medicare & Medicaid Services (CMS). 2026d. "Health Insurance Exchange Public Use Files (Exchange PUFs)." Data through plan year 2027, 2026 updates. CMS data catalog.

  • Dafny, Leemore, Jonathan Gruber, and Christopher Ody. 2015. "More Insurers Lower Premiums: Evidence from Initial Pricing in the Health Insurance Marketplaces." American Journal of Health Economics 1 (1): 53–81. Journal DOI.

  • Ericson, Keith M. Marzilli, and Amanda Starc. 2016. "How Product Standardization Affects Choice: Evidence from the Massachusetts Health Insurance Exchange." Journal of Health Economics 50: 71–85. Journal DOI.

  • Federal Office of Public Health (Switzerland). 2026a. "Health Insurance: Premiums and Co-Payment." Federal guidance.

  • Federal Office of Public Health (Switzerland). 2026b. "Health Insurance: Comparison of Premiums." Premium approval and Priminfo.

  • Federal Office of Public Health (Switzerland). 2026c. "Health Insurance: Risk Compensation." Risk-compensation description.

  • Gaynor, Martin, and Amanda Starc. 2026. "Competition in Health Insurance Markets." Journal of Economic Perspectives 40 (2): 17–42. Journal DOI.

  • Government of the Netherlands. 2026. "Standard Health Insurance." Government guidance.

  • Handel, Benjamin R., and Jonathan T. Kolstad. 2015. "Health Insurance for 'Humans': Information Frictions, Plan Choice, and Consumer Welfare." American Economic Review 105 (8): 2449–2500. Journal DOI.

  • HealthCare.gov. 2026a. "How Health Insurance Marketplace Plans Set Your Premiums." Consumer rating guidance.

  • HealthCare.gov. 2026b. "Health Plan Categories: Bronze, Silver, Gold and Platinum." Plan category guidance.

  • KFF. 2026. "Marketplace Average Monthly Benchmark Premiums." State Health Facts, 2026 data. State benchmark series.

  • Ortaliza, Jared, Justin Lo, Matt McGough, and Cynthia Cox. 2026. "How Has Insurer Participation in the ACA Marketplaces Changed in 2026?" KFF, June 11, corrected June 22, 2026. Insurer participation analysis.

  • United States Department of Health and Human Services (HHS). 2026a. 45 CFR § 153.320, "Federally Certified Risk Adjustment Methodology." Codified regulation.

  • United States Department of Health and Human Services (HHS). 2026b. "Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program." Federal Register 91 (97), May 20, 2026, 29526–29877. Official final rule.

  • United States Department of the Treasury. 2026. 26 CFR § 1.36B-3, "Computing the Premium Assistance Credit Amount." Codified tax regulation.

  • United States Government Accountability Office (GAO). 2026. "Private Health Insurance: Market Concentration in 2024 Was Generally Higher Than in 2011." GAO-27-108927, October 16, 2026. GAO report.

  • United States Congress. 2026. 26 USC § 36B, "Refundable Credit for Coverage Under a Qualified Health Plan." Current codified text, accessed November 2026. Statutory text.

  • Zorginstituut Nederland. 2026. "Risicoverevening Zvw." Administrative description and annual health insurance risk equalization resources. Official Dutch administration.